Pharma Stocks Outlook for the week - 28.11.2016 to 02.12.2016
Click Here & Register To Get 2 days Trial Tips
The stocks of pharmaceutical companies are likely to be mixed next week but the general trend in the sector is expected to be positive as investors may buy some quality stocks with strong fundamentals. The outlook on the pharmaceutical sector over the long term is positive, especially on companies that have a good managerial record and have significant exposure to the US. While there are regulatory issues, the US market provides a significant opportunity to the Indian pharmaceutical segment. Profits for generic drug manufacturers are likely to receive a boost in the US as President-elect Donald Trump has indicated that he wants to bring down the cost of healthcare in the country. The sentiment over the stock has been under pressure after US Food and Drug Administration issued a warning to its UK-based step-down subsidiary CP Pharmaceuticals. While the arm does not export products to the US, it adds to the existing regulatory issues of Wockhardt. The Mumbai-based pharmaceutical company's facility at Ankleshwar in Gujarat is already under an import alert for violations of good manufacturing practices. Next week, market participants may also keep an eye on broader markets, in which the rebound is expected to continue.
Click Here & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753
The stocks of pharmaceutical companies are likely to be mixed next week but the general trend in the sector is expected to be positive as investors may buy some quality stocks with strong fundamentals. The outlook on the pharmaceutical sector over the long term is positive, especially on companies that have a good managerial record and have significant exposure to the US. While there are regulatory issues, the US market provides a significant opportunity to the Indian pharmaceutical segment. Profits for generic drug manufacturers are likely to receive a boost in the US as President-elect Donald Trump has indicated that he wants to bring down the cost of healthcare in the country. The sentiment over the stock has been under pressure after US Food and Drug Administration issued a warning to its UK-based step-down subsidiary CP Pharmaceuticals. While the arm does not export products to the US, it adds to the existing regulatory issues of Wockhardt. The Mumbai-based pharmaceutical company's facility at Ankleshwar in Gujarat is already under an import alert for violations of good manufacturing practices. Next week, market participants may also keep an eye on broader markets, in which the rebound is expected to continue.
Click Here & Register To Get 2 days Trial Tips
Free Intraday Tips : Join Our Whatsapp No : 9841986753
